Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of HPV subtypes not covered by the nine-valent vaccine in patients with CIN 2-3 and cervical squamous cell carcinoma.

Current problems in cancer - 1 Dec 2021

Ma Ming-Jun, Wang Ya-Nan, Zhu Jing-Fen, Wang Xiao-Yun, Jin Yu-Biao, Liu Xiang-Nan, Wu Su-Fang, Yang Yong-Bin

Abstract excerpt

BACKGROUND: As the second most common female malignant tumor, cervical cancer is also one of the most preventable and avoidable cancers. The World Health Organization has launched a global plan to accelerate the elimination of cervical cancer. Therefore, in the era of postvaccine, the role of HPV subtypes in cervical precancerous lesions and cervical cancer that are not covered by vaccine should be further...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to China

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Papillomavirus Vaccines

Share to Uterine Cervical Dysplasia

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 34154817
DOI: 10.1016/j.currproblcancer.2021.100761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of HPV subtypes not covered by the nine-valent vaccine in patients with CIN 2-3 and cervical squamous cell carcinoma.PMID 34154817Read ↗

The distribution and pathogenic risk of non-9-valent vaccine covered HPV subtypes in cervical lesions.Semantic proximity Read ↗

Candidate HPV genotypes not included in the 9-valent vaccine for prevention of CIN 2-3.Semantic proximity Read ↗

The use of the HPV vaccine in a group of primarily unvaccinated HPV-positive patients.Semantic proximity Read ↗

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.Semantic proximity Read ↗

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions.Semantic proximity Read ↗

Respective prevalence of high-risk HPVgenotypes in cervical neoplasia in Senegal.Semantic proximity Read ↗

Potential impact of introducing a nonavalent HPV vaccination.Semantic proximity Read ↗

Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).Semantic proximity Read ↗

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.Semantic proximity Read ↗

Prevalence of Vaccine-Covered and Non-Covered HPV Genotypes Among Unvaccinated Women in Ankara: A Single-Center StudySemantic proximity Read ↗

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.Semantic proximity Read ↗

HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.